biostudies-literatureUnknown3(2)Kimura K<h4>Objective</h4>To compare effects of natalizumab on inflammatory and regulatory T cells with regard to expression of α4-integrin (CD49d).<h4>Methods</h4>Twenty-seven natalizumab-naive and 8 natalizumab-treated patients with multiple sclerosis (MS), 7 patients with neuromyelitis optica (NMO) or NMO spectrum disorder, and 8 healthy controls were included. The positive rate of CD49d was analyzed and compared among T helper 1 (Th1), T helper 17 (Th17), and regulatory T (Treg) cells (CD49d+Th1, CD49d+Th17, and CD49d+Treg, respectively).<h4>Results</h4>Natalizumab treatment increased CD49d ratios, CD49d+Th1/CD49d+Treg, and CD49d+Th17/CD49d+Treg. This indicates larger reduction of the CD49d+ population in Treg cells than in Th1 or Th17 cells. The CD49d ratios of 2 patients who experienced exacNeurology(R) neuroimmunology & neuroinflammatione210https://www.ebi.ac.uk/biostudies/studies/S-EPMC4784802biostudies-literatureDisrupted balance of T cells under natalizumab treatment in multiple sclerosis.PMC4784802Nakamura MTakahashi RMurata MLin YKimura KOkamoto TAraki MYamamura TSato WfalseDisrupted balance of T cells under natalizumab treatment in multiple sclerosis.<h4>Objective</h4>To compare effects of natalizumab on inflammatory and regulatory T cells with regard to expression of α4-integrin (CD49d).<h4>Methods</h4>Twenty-seven natalizumab-naive and 8 natalizumab-treated patients with multiple sclerosis (MS), 7 patients with neuromyelitis optica (NMO) or NMO spectrum disorder, and 8 healthy controls were included. The positive rate of CD49d was analyzed and compared among T helper 1 (Th1), T helper 17 (Th17), and regulatory T (Treg) cells (CD49d+Th1, CD49d+Th17, and CD49d+Treg, respectively).<h4>Results</h4>Natalizumab treatment increased CD49d ratios, CD49d+Th1/CD49d+Treg, and CD49d+Th17/CD49d+Treg. This indicates larger reduction of the CD49d+ population in Treg cells than in Th1 or Th17 cells. The CD49d ratios of 2 patients who experienced exac2016-01-01T00:00:00Z2016 Apr2025-04-25T18:59:20.642Z2019-03-27T02:10:45ZS-EPMC47848022700697110.1212/NXI.0000000000000210